ArticleNature medicine2016
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
161citing papers in PubMed, 2 pooled it
18.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 2 syntheses or guidelines pooled it, 246 citations in OpenAlex.
- Molecular Landscape of Acute Myeloid Leukemia in Pediatric Patient-Age-Related Correlations: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- The Coming of Age of Preclinical Models of MDS.Frontiers in oncology · 2022Pooled it
- Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.Leukemia research · 2022Trial
- Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.Blood advances · 2021Trial
- Prognostic Significance of Secondary-Type Mutations in NPM1-Mutated Acute Myeloid Leukemia.Cancer medicine · 2026Article
- Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.The Journal of clinical investigation · 2026Article
- Epigenetic Regulation in Acute Myeloid Leukemia: Molecular Mechanisms and Clinical Implications.Cancers · 2026Review
- Ligature-induced periodontitis promotesHaematologica · 2026Article
- DNMT3A in cancer: from epigenetic writer to oncogenic driver.Clinical epigenetics · 2026Review
- Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.Cell reports. Medicine · 2026Article
- Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML.Cancer discovery · 2026Article
- DNMT3A R882H Is Not Required for Disease Maintenance in Primary Human AML but Is Associated with Increased Leukemia Stem Cell Frequency.Cancer discovery · 2026Article
- Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.Leukemia · 2026Article
- Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes.medRxiv : the preprint server for health sciences · 2025Article
- Non-canonical functions of DNMT3A in hematopoietic stem cells regulate telomerase activity and genome integrity.Cell stem cell · 2025Article
- Epigenetic regulation of cancer stemness.Signal transduction and targeted therapy · 2025Review
- Clonal hematopoiesis in myeloid malignancies and solid tumors.Nature cancer · 2025Review
- Article
- Article
- Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions.International journal of molecular sciences · 2025Review
101 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
39 authors at 9 institutions in 3 countries.
Olga A GuryanovaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kaitlyn ShankHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Barbara SpitzerDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Luisa LucianiUniversity of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Francine E Garrett-BakelmanDivision of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Chezi GanzelDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Benjamin H DurhamHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Abhinita MohantyDiagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Gregor HoermannDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Sharon A RiveraIrving Cancer Research Center, Columbia University, New York, New York, USA.
Alan G ChramiecCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Elodie PronierHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lennart BastianHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Matthew D KellerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Daniel TovbinHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Evangelia LoizouCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Abby R WeinsteinHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Adriana Rodriguez GonzalezHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Yen K LieuIrving Cancer Research Center, Columbia University, New York, New York, USA.
Jacob M RoweDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Friederike PastoreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Anna Sophia McKenneyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Andrei V KrivtsovCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-5511-1686
Wolfgang R SperrDivision of Hematology and Hemostaseology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Justin R CrossDonald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Christopher E MasonDepartment of Physiology and Biophysics and the Institute for Computational Biomedicine, Weill Cornell Medical College of Cornell University, New York, New York, USA.ORCID 0000-0002-1850-1642
Martin S TallmanLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Maria E ArcilaDiagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Scott A ArmstrongDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Stefan KubicekChristian Doppler Laboratory for Chemical Genetics and Anti-Infectives, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.ORCID 0000-0003-0855-8343
Philipp B StaberDivision of Hematology and Hemostaseology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
Mithat GönenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Elisabeth M PaiettaDepartment of Oncology, Montefiore Medical Center, Bronx, New York, USA.
Ari M MelnickDivision of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Stephen D NimerUniversity of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
Siddhartha MukherjeeIrving Cancer Research Center, Columbia University, New York, New York, USA.
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Memorial Sloan Kettering Cancer Center · USColumbia University Irving Medical Center · USCornell University · USComprehensive Cancer Center Vienna · ATShaare Zedek Medical Center · ILUniversity of Miami · USAustrian Academy of Sciences · ATMedical University of Vienna · ATMontefiore Medical Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MWeill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MMSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3MNetwork Lead Academic Participating Site: Memorial Sloan-Kettering Cancer CenterU10CA180791 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AGHAJANIAN, CAROL, MORRIS, MICHAEL J · 2014 to 2018
$4.6MECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0MGenetic Dissection of Acute Myeloid Leukemia.R01CA169784 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2014 to 2018
$1.8MBiologic and therapeutic relevance of DNMT3A mutations in acute myeloid leukemiaR00CA178191 · NCI · UNIVERSITY OF FLORIDA · PI GURYANOVA, OLGA A · 2016 to 2018
$759kGenetic and epigenetic basis of relapse in acute myeloid leukemiaK08CA169055 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI GARRETT-BAKELMAN, FRANCINE EVALINA · 2012 to 2016
$742kAustrian Science Fund FWF P 27132NCI NIH HHS K08 CA169055NCI NIH HHS K12 CA184746NCI NIH HHS K99 CA178191NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA178191NCI NIH HHS R01 CA169784NCI NIH HHS U10 CA180791NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189859NIGMS NIH HHS T32 GM007739
Abstract
Although the majority of patients with acute myeloid leukemia (AML) initially respond to chemotherapy, many of them subsequently relapse, and the mechanistic basis for AML persistence following chemotherapy has not been determined. Recurrent somatic mutations in DNA methyltransferase 3A (DNMT3A), most frequently at arginine 882 (DNMT3A
Indexed as
AnimalsAnthracyclinesAntineoplastic AgentsCell Line, TumorCell ProliferationCell SurvivalChromatin Assembly and DisassemblyDaunorubicinDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADrug Resistance, Neoplasmfms-Like Tyrosine Kinase 3Hematopoietic Stem CellsHumansImmunoblottingImmunoprecipitationAnthracyclinesAntineoplastic AgentsDaunorubicinDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanDnmt3a protein, mousefms-Like Tyrosine Kinase 3NPM1 protein, humanNpm1 protein, mouseNuclear ProteinsNucleophosminNucleosomes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.